About US
Contact us
-
AbbVie's Skyrizi bests Novartis' Cosentyx in head-to-head psoriasis matchWith its megamerger with Allergan closed and Humira's decline staring it in the face, AbbVie is looking for growth from its two recent launches, psoriasis med Skyrizi and rheumatoid arthritis drug Ri2020/6/15
-
AstraZeneca's Farxiga cuts risk of diabetes onset in heart failure patientsAstraZeneca diabetes drug Farxiga last month scored a first-in-class FDA nod, winning clearance to reduce cardiovascular risks for certain heart failure patients without diabetes. Now, the British dr2020/6/12
-
Novo Nordisk's long-lasting insulin candidate matches Lantus in phase 2Novo Nordisk has long been working on drugs that can help people earlier on in their diabetes and keep them from progressing to insulin treatment. But that doesn’t mean it’s not also working to impro2020/6/12
-
Lilly's Trulicity tops Ozempic at keeping patients compliant, real-world data showEli Lilly is fighting hard to protect Trulicity's share against Novo Nordisk’s newest offerings in the GLP-1 class, and it’s breaking out real-world data to support its case. A new real-world analysi2020/6/11
-
Sanofi bolsters Soliqua with real-world data showing starting insulin, GLP-1 together helps control blood sugarSanofi’s Soliqua combines an insulin with a GLP-1 agonist, and, according to a new real-world study, delivering those two therapies simultaneously is the way to go. Starting an insulin and a GLP-1 dr2020/6/11
-
AstraZeneca ditches plan for Gilead merger amid industry skepticism: reportThe excitement over a potential record-setting megamerger between AstraZeneca and Gilead Sciences looks short-lived. AstraZeneca has already ditched its interest in a marriage with Gilead, The Times2020/6/10
-
AbbVie's Humira defense may keep prices high, but it's still legal, judge rulesAbbViereaps billions of dollars annually fromits big-selling immunology medicine Humira, and, under deals with biosimilar makers, the drugis likely free from U.S. competition until 2023.A classof pur2020/6/10
-
FDA official leaves 'Warp Speed' to preserve independent regulatory power: reportWelcome to theFiercePharmapolitical roundup, where each Monday we’ll highlight developments in Washington, D.C., and elsewherethat could affect drug pricing and how drugmakers operate. As rese2020/6/9
-
AstraZeneca reportedly eyed a merger with Gilead. But does 'Gileaz' make sense?Six years ago, AstraZeneca CEO Pascal Soriot fought off Pfizer’s $118 billion takeover attempt. Now, the defender is reportedly playing offense, going after a deal of similar size. The British pharma2020/6/9
-
'Onshoring' drug manufacturing; Takeda's IBD pipeline cull; Legend's $350M IPOThe pharma industry is pushing backat the government's call to "onshore" manufacturing for the U.S. market.Takeda decided to stop development of Shire's SHP647, a drug the European Commission had ask2020/6/8